安尔碘或过氧化氢溶液联合阿奇霉素治疗宫颈支原体感染的疗效观察

目的探讨安尔碘或过氧化氢溶液联合阿奇霉素治疗宫颈支原体感染的疗效. 方法采用完全随机对照试验研究方法,将2004年6月至2005年7月清华大学玉泉医院妇科门诊宫颈分泌物支原体(Uu或Mh)培养阳性者随机分成3组,对照组为单纯应用阿奇霉素治疗组;观察Ⅰ组为安尔碘液联合阿奇霉素用药组;观察Ⅱ组为过氧化氢溶液联合阿奇霉素用药组.各组分别于治疗开始的第10天进行宫颈拭子支原体培养,阳性者间隔两周再次复查,根据培养结果,结合症状、体征判断疗效. 结果观察Ⅰ组、观察Ⅱ组和对照组的临床有效率分别为93.3%、90.0%和 50.0%,两观察组分别与对照组比较差异均有显著性意义 (P<0.05). 两观察组之间比较差异无显著性意义(P>0.05). 结论安尔碘液或过氧化氢溶液与阿奇霉素联合用药均为治疗宫颈支原体感染的有效方法.     

干扰素栓联合阿奇霉素治疗衣原体、支原体性宫颈炎的疗效观察

目的评价联合干扰素栓与阿奇霉素治疗衣原体、支原体性宫颈炎的疗效。方法选取我院2014年1月~12月收治的支原体或衣原体感染的宫颈炎患者56例,将其随机分为对照组和观察组,各28例。对照组采用干扰素栓进行治疗,观察组在对照组的基础上联合阿奇霉素进行治疗。比较两组患者的疗效、转阴时间及治疗时间。结果观察组总有效率为92.9%,明显高于对照组的67.9%;观察组转阴时间和治疗时间明显少于对照组;差异均有统计学意义(P0.05)。结论联合干扰素栓与阿奇霉素治疗衣原体、支原体性宫颈炎,具有明显的疗效,值得临床应用及推广。     

阿奇霉素联合干扰素栓治疗宫颈炎的疗效及安全性评价

目的观察并且分析阿奇霉素联合干扰素栓用药对于宫颈炎患者的疗效。方法将我院收治的患者100例作为研究对象,随机分成对照组和实验组,各50例。对照组患者进行干扰素栓治疗,实验组进行干扰素栓、阿奇霉素联合治疗。观察两组患者疗效。结果对照组治疗总有效率为72%,实验组治疗总有效率为92%。对两组患者进行随访记录,实验组患者病原体的转阴率高于对照组。结论阿奇霉素联合干扰素栓用药对于治疗宫颈炎的疗效明显。     

阿奇霉素联合小儿清肺颗粒治疗儿童肺炎支原体肺炎疗效观察

目的观察阿奇霉素联合小儿清肺颗粒治疗儿童肺炎支原体肺炎的临床效果。方法河南省睢县人民医院儿科2012年11月至2014年9月收治肺炎支原体肺炎患儿40例,随机分为对照组与观察组各20例。对照组实施阿奇霉素治疗,观察组采取阿奇霉素与小儿清肺颗粒联合治疗,治疗10d为1个疗程。观察两组患儿临床疗效及X线阴影消失时间及头痛缓解时间、发热缓解时间。结果对照组治疗后总有效率为65.0%(13/20),显著低于观察组95.0%(19/20),差异有统计学意义(P0.05);观察组治疗后头痛缓解时间、发热缓解时间及X线阴影消失时间均较对照组短,差异有统计学意义(P0.05)。结论小儿肺炎支原体肺炎采取小儿清肺颗粒与阿奇霉素联合治疗疗效显著,患儿症状及体征能快速改善。     

咳平汤联合阿奇霉素治疗小儿支原体肺炎50例疗效观察

目的观察咳平汤联合阿奇霉素治疗小儿支原体肺炎的临床疗效。方法将100例支原体肺炎患儿随机分为观察组和对照组各50例,观察组应用中药咳平汤联合阿奇霉素注射液进行治疗;对照组单纯应用阿奇霉素注射液治疗。2个疗程后观察患儿咳嗽、咯痰消失时间及疗效。结果观察组总有效率96%（48/50）高于对照组84%（42/50）,差异有统计学意义（P〈0.05）;观察组6d内咳嗽、咯痰消失例数优于对照组,差异有统计学意义（P〈0.05）。结论咳平汤联合阿奇霉素治疗小儿支原体肺炎疗效显著。     

阿奇霉素治疗肺炎支原体肺炎临床分析

目的:观察阿奇霉素静滴治疗肺炎支原体肺炎的疗效。方法:将40例患儿随机分为2组,治疗组20例静滴阿奇霉素,对照组20例静滴红霉素,其余治疗相同。结果:治疗组总有效率85%,对照组总有效率70%。结论:阿奇霉素静滴治疗肺炎支原体肺炎退热快,胃肠道反应小,疗程缩短。     

阿奇霉素联合细辛脑注射液治疗小儿支原体肺炎64例疗效观察

目的：比较阿奇霉素联合细辛脑注射液治疗小儿支原体肺炎疗效。方法：将64例小儿支原体肺炎患儿随机分成两组，每组各32例。对照组采用阿奇霉素10mg／kg，溶解5％葡萄糖液中静脉滴注，治疗组在对照组基础上加用细辛脑注射液静滴。结果：治疗后，治疗组临床症状、体征减轻和消失的时间明显短于对照组，两组比较差异有统计学意义（P〈0．05％）。     

阿奇霉素治疗儿童支原体肺炎的临床疗效观察

目的:观察和探讨阿奇霉素和红霉素治疗儿童支原体肺炎的临床疗效的对比。方法:采用对比法,选取我院2009年～2011年支原体肺炎儿童患者68例,分为治疗组和对照组各34例,治疗组使用阿奇霉素治疗,对照组使用红霉素治疗,观察对比两组治疗效果。结果:两组患者的疗效及不良反应发生率对比差异显著(P<0.05),具体统计学意义。结论:阿奇霉素在治疗儿童的支原体肺炎有显著的疗效,优于红霉素,且不良反应小。值得临床推广使用。     

阿奇霉素联合布地奈德混悬液雾化吸入治疗小儿肺炎支原体肺炎53例疗效观察简

目的 观察阿奇霉素联合布地奈德混悬液雾化吸入治疗小儿肺炎支原体肺炎的临床疗效.方法 采用随机数字表法将105例确诊为支原体肺炎的患儿分为两组,对照组52例给予阿奇霉素联合盐酸氨溴索治疗,观察组53例在给予阿奇霉素的同时,给予布地奈德混悬液联合硫酸特布他林雾化吸入治疗,观察两组患儿的临床疗效、临床症状与体征改善情况.结果 观察组总有效率94.3%,明显优于对照组的80.8%,差异有统计学意义（P＜0.05）;观察组喘憋缓解时间、啰音消失时间以及咳嗽缓解时间明显短于对照组,差异均有统计学意义（P＜0.01）;治疗期间未发现与研究药物相关的不良反应.结论 阿奇霉素联合布地奈德混悬液雾化吸入治疗小儿肺炎支原体肺炎疗效确切,能够通过雾化吸入直接作用于病变部位,降低气道高反应性,在改善临床症状、体征和提高患儿生存质量方面具有重要的作用,值得临床推广应用.     

热毒宁注射液佐治小儿肺炎支原体肺炎85例疗效观察

目的观察阿奇霉素联合热毒宁注射液治疗小儿肺炎支原体肺炎的临床疗效。方法将164例肺炎支原体肺炎患儿随机分为观察组85例和对照组79例,两组均使用阿奇霉素粉针静脉滴注,观察组在此基础上加用热毒宁注射液静脉滴注治疗,观察两组临床退热时间、咳嗽明显好转时间、平均住院时间及副反应。结果观察组在退热时间、咳嗽明显好转时间及平均住院时间均短于对照组,差异有统计学意义（P〈0.05）,且未发现不良反应。结论阿奇霉素联合热毒宁注射液治疗小儿肺炎支原体肺炎有较好疗效。     

Association between genital mycoplasma and cervical squamous cell atypia

ObjectivesTo investigate the existence of an association between genital mycoplasma infections and cervical squamous cell atypia.Study designProspective cross-sectional study.SettingDepartment of Obstetrics and Gynecology, in collaboration with the Clinical Pathology and Pathology Departments, Faculty of Medicine, Benha University, Egypt.Patients and methodsThree-hundred women were scheduled into two equal groups. The control group included 150 women with negative Pap smear for cervical atypia. The study group included 150 women with cervical squamous cell atypia proved by Pap smear. Swabs obtained from endocervix and posterior vaginal fornix were subjected to culture for detection of genital mycoplasma using Mycoplasma IST2. Outcome measures were the rates of cervicovaginal infection with genital mycoplasma in both groups, and estimation of the co-occurrence of genital mycoplasma and cervical squamous cell atypia.ResultsUsing Mycoplasma IST2 kit genital mycoplasmas were positive in (49.33% vs. 28.67%) of cases in study and control groups, respectively. Ureaplasma urealyticum was isolated more frequent than mycoplasma hominis and mixed mycoplasma infection. U. urealyticum colonization was demonstrated in women with HSIL (57.5%) significantly more frequent compared to women with LSIL (36.59%), ASCUS (30.43%), and with normal cytology (21.33%); P = 0.019.ConclusionUreaplasma urealyticum was present significantly more often in women with cervical cytological atypia, suggesting the existence of an association between cervicovaginal infections with U. urealyticum and precancerous lesions of the uterine cervix.     

间歇性导尿在宫颈癌根治术后患者膀胱功能恢复及预防泌尿系统感染的应用研究

目的:分析间歇性导尿在宫颈癌根治术后患者膀胱功能恢复及预防泌尿系统感染的临床意义。方法:选取中国人民解放军总医院妇产科2014年1月—2016年12月收治的早期宫颈癌(FIGOⅠA期、ⅠB期、ⅡA期)手术后残余尿量不合格患者182例,于手术后第10天拔除尿管,测残余尿量≥100 mL者为不合格。随机分为观察组(89例)和对照组(93例),观察组采用间歇性导尿及个体化精准护理,对照组采用留置尿管及常规护理。记录2组患者一般情况,比较2组患者残余尿量合格需要的时间和泌尿系统感染情况。结果:2组患者年龄、手术方式、FIGO分期、残余尿量分级比较差异无统计学意义(均P>0.05)。残余尿量100~200 mL、201~350 mL者中,观察组残余尿量合格需要的时间少于对照组,差异有统计学意义(均P<0.001),观察组泌尿系统感染发生率低于对照组,差异有统计学意义(均P<0.05)。结论:间歇性导尿能够促进宫颈癌根治术后患者膀胱功能恢复、降低泌尿系统感染发生率,该方法操作简便、患者易接受、临床效果满意,适合推广应用。     

On the etiologic role of ureaplasma urealyticum (T-mycoplasma) infection in infertility

Two hundred consecutive infertility patients and sixty-seven controls subjects were studied for the incidence of infection with Ureaplasma urealyticum (T-mycoplasma). On the basis of a complete infertility investigation, the infertility patients were subdivided into those with explained infertility and those with unexplained infertility. Of the patients with unexplained infertility, 55% had a positive culture for T-mycoplasma as compared with a 32% incidence of positive cultures in the control population. The differences were statistically significant. The 6-month pregnancy rate following successful antibiotic treatment in patients with unexplained infertility was 42%. The 6-month pregnancy rate in a comparable group of patients with unexplained infertility, seen during a 3-year period prior to mycoplasma culture and treatment, was 32%. The difference in pregnancy rates between the two groups was not statistically significant. No correlation was found between a poor postcoital test and the presence of T-mycoplasma infection nor between T-mycoplasma infection and poor cervical mucus. The role of T-mycoplasma infection in infertility was neither proven nor disproven by this study.     

孕妇支原体感染与低出生体重儿的红霉素干预实验

目的探索孕妇生殖道支原体感染与低出生体重儿的病因学关系.方法经产前检查支原体阳性孕妇488例,按实验分组方法随机分成红霉素干预组和非干预组,比较两组间孕妇支原体感染阴转率、母耍传播率和低出生体重儿的发生率.结果红霉素干预组解脲脲原体(Ureaplasma urealyticum,Uu)的阴转率和母耍传播率低于非干预组,差异有显著性(P＜0.05),而人型支原体(Mycoplasma hominis,Mh)的阴转率及母耍传播率在组间无显著性差异(P＞0.05).干预组中低出生体重儿的发生率显著低于非干预组(P＜0.05).结论红霉素干预措施能有效地降低孕妇解脲脲原体感染,阻断其母耍传播,降低低出生体重儿发生率.     

The prevalence of ureaplasma, mycoplasma and antibodies against chlamydia group antigen in gynecological outpatients

177 women with an average age of 30 years were investigated for ureaplasma, mycoplasma and for antibodies against the chlamydia group antigen. Specimen of endocervical mucus and catheter specimens of urine were cultured and the ELISA ("enzyme-linked immunosorbent assay") technique applied. In addition the purity class (I to III) of gram-stained vaginal smears was determined. Ureaplasma were isolated from 45.8 and 26.0%, mycoplasma from 9.0 and 7.9% of cervical and urine specimens respectively. The patients were divided into 5 clinical groups. Patients in the first three groups (I-III, inflammatory disorders, bleeding anomalies, benign and malignant neoplasms of the genital tract) showed a significantly (p less than or equal to 0.05) higher colony count of ureaplasma in their urine than patients in the other two groups (IV and V, who had attended the hospital for reproductive problems or for routine examination). There was a clear correlation between the isolation rates of ureaplasma and mycoplasma and the purity classes of the vaginal smears. The rate of isolation increased progressively with class II and III smears. Antibodies against the chlamydia group antigen were detected in about 40% of all sera tested. A very high titer of antibodies reflecting a recent chlamydial infection was found in 11% of the sera tested.     

肾移植术后免疫抑制剂治疗对人乳头瘤病毒感染及宫颈癌发生率的影响

目的:通过肾移植术后接受免疫抑制治疗的女性患者的人乳头瘤病毒(HPV)感染及宫颈癌发生率与同期我院妇科女性患者的对比,探讨肾移植术后免疫抑制治疗对女性高危型HPV感染及宫颈癌发生率的影响,为肾移植术后患者高危型HPV感染和宫颈癌的早期诊断和防治提供依据。方法:选取在我院行肾移植术的女性患者中,无其他器官移植,移植前无HPV感染、宫颈上皮内瘤变(CIN)及宫颈癌的患者865例作为研究组,选取我院妇科同期未进行器官移植的患者作为对照组,比较分析2组高危型HPV感染和宫颈癌发病情况。结果:研究组患者的高危型HPV感染率、CINⅢ及宫颈癌发生率均高于对照组,差异有统计学意义(均P<0.001);而研究组中高危型HPV感染、CINⅢ及宫颈癌的平均发病年龄与对照组比较差异均无统计学意义(均P>0.05)。结论:肾移植术后免疫抑制治疗不会使患者HPV感染及宫颈癌的发病年龄提前,但可能导致发生率增高。     

Routine cervical dilatation during elective cesarean section and its influence on maternal morbidity: a randomized controlled study

AIM: To determine the effect of routine intraoperative cervical dilatation during elective cesarean section on maternal morbidity. SUBJECTS AND METHODS: Patients with even numbers in the operative elective cesarean section list were included in the study. Of these, every second patient underwent intraoperative cervical dilatation. All participants in the two groups had otherwise similar preoperative care, operative procedures and subsequent clinical care. Blood loss was estimated and maternal infection status was assessed postoperatively by any rise of temperature or wound infection. RESULTS: Of the 131 patients included in the study, 67 underwent cervical dilation and 64 served as controls. There was no significant difference in postoperative hemoglobin, incidence of fever, or wound infection between the two groups. Only two of the cervical dilation group and one control patient developed postoperative fever. A hemoglobin drop of more than 0.5 g/dL was noted in 27 and 26 patients in the cervical dilation and the no dilation groups, respectively (NS). None of the study patients had signs of wound infection. CONCLUSION: Intraoperative cervical dilatation during elective cesarean section did not reduce the risk of postoperative maternal fever, wound infection or change in hemoglobin concentration.     

The congruity between urine and cervical swab cultures in pregnant women with versus without amniotic fluid infection

INTRODUCTION: We observed the congruity of bacteria found in urine and cervix of pregnant women with amniotic fluid infection (AFI) compared to healthy controls. PATIENTS AND METHODS: Over three years, we prospectively analysed urine and cervical swabs cultures in 120 pregnant women in gestational week 16-20. The patient population was divided in two groups: group I patients had clinical symptoms of AFI. The rest of the patients were designated as healthy controls (group II). Congruity between findings in both groups was observed. In patients with bacterial growth, antibiotic treatment was initiated as recommended and once ended - culture probes were repeated. RESULTS: The rates of nonsignificant and significant bacteriuria were doubled in group I. Fifty-five percent (n = 33) of patients in group I had identical bacteria cultured both from the urine sample and cervical swab, in contrast to only 13.3 % in group II. Congruity was most pronounced for Klebsiella species and E. coli, the later being single most dominant isolate in regards to both cultures. After antimicrobial treatment, microbial eradication occurred in 15 patients (45.5 %). The observed incidences of abortions and preterm deliveries were significantly lower in patients with microbial eradication versus patients with microbial persistence. CONCLUSION: Patients with clinical symptoms of AFI have high risk for bacteriuria identical to bacterial culture from cervical swab. Antimicrobial treatment was effective only partially where indicated. Screening for eradication is recommended and consensus on the most appropriate therapy is needed.     

Role of immunomodulatory treatment with Iscador QuS and Intron A of women with CIN1 with concurrent HPV infection

OBJECTIVE: The paper presents the role of immunomodulatory treatment with Iscador QuS and Intron A of women with CIN1 and CIN2 with concurrent HPV infection. MATERIAL AND METHODS: Clinical material consisted of 96 women aged 18-52 years of life. The women were divided into three groups. Group A (35 women) treated with Iscador QuS administered s.c. twice a week for 3 months, group B (30 women) treated with Intron A, administered twice a week in the cervical injections for 3 months and control group K (31 women) without treatment followed up with cytology and colposcopy. RESULTS: In the group A (Iscador QuS) CIN remission was observed in slightly higher percentage (non significant) comparing to the control group. In the group B (Intron A) remission CIN was observed in 24 (80%) cases which was statistically significant comparing to the control and A groups. There were no progression of CIN in the group B and the stationery process was observed statistically more frequent comparing to the control and A groups. There was observed statistically higher percentage of cases without HPV infection in all groups during the experiment. The remission concerned both high and low oncogenic potency viruses. In the highest percentage CIN with concurrent HPV infection remission was observed in the B (Intron A) group. CONCLUSIONS: 1/Iscador QuS and specially Intron A increases the CIN1 and CIN2 remission rate. 2/These two agents may also affect the HPV remission.